WO2009131553A3 - Methods of altering bone growth by administration of sost or wise antagonist or agonist - Google Patents

Methods of altering bone growth by administration of sost or wise antagonist or agonist Download PDF

Info

Publication number
WO2009131553A3
WO2009131553A3 PCT/US2007/088542 US2007088542W WO2009131553A3 WO 2009131553 A3 WO2009131553 A3 WO 2009131553A3 US 2007088542 W US2007088542 W US 2007088542W WO 2009131553 A3 WO2009131553 A3 WO 2009131553A3
Authority
WO
WIPO (PCT)
Prior art keywords
sost
bone growth
sost antagonist
antagonist
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/088542
Other languages
French (fr)
Other versions
WO2009131553A2 (en
Inventor
Debra L. Ellies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OsteoGeneX Inc
Original Assignee
OsteoGeneX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39584303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009131553(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by OsteoGeneX Inc filed Critical OsteoGeneX Inc
Priority to ES07875255.7T priority Critical patent/ES2666650T3/en
Priority to EP07875255.7A priority patent/EP2144613B1/en
Priority to JP2010509325A priority patent/JP2010528002A/en
Priority to EP18157578.8A priority patent/EP3345607B1/en
Priority to EP22200370.9A priority patent/EP4176884A1/en
Anticipated expiration legal-status Critical
Publication of WO2009131553A2 publication Critical patent/WO2009131553A2/en
Publication of WO2009131553A3 publication Critical patent/WO2009131553A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug.
PCT/US2007/088542 2006-12-29 2007-12-21 Methods of altering bone growth by administration of sost or wise antagonist or agonist Ceased WO2009131553A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES07875255.7T ES2666650T3 (en) 2006-12-29 2007-12-21 Methods to alter bone growth by administration of antagonist or agonist of support or wise
EP07875255.7A EP2144613B1 (en) 2006-12-29 2007-12-21 Methods of altering bone growth by administration of sost or wise antagonist or agonist
JP2010509325A JP2010528002A (en) 2006-12-29 2007-12-21 Method for altering bone growth by administration of a SOST or WISE antagonist or agonist
EP18157578.8A EP3345607B1 (en) 2006-12-29 2007-12-21 Methods of altering bone growth by administration of sost or wise antagonist or agonist
EP22200370.9A EP4176884A1 (en) 2006-12-29 2007-12-21 Methods of altering bone growth by administration of sost or wise antagonist or agonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88264206P 2006-12-29 2006-12-29
US60/882,642 2006-12-29

Publications (2)

Publication Number Publication Date
WO2009131553A2 WO2009131553A2 (en) 2009-10-29
WO2009131553A3 true WO2009131553A3 (en) 2010-04-29

Family

ID=39584303

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/088542 Ceased WO2009131553A2 (en) 2006-12-29 2007-12-21 Methods of altering bone growth by administration of sost or wise antagonist or agonist

Country Status (12)

Country Link
US (9) US8178099B2 (en)
EP (3) EP3345607B1 (en)
JP (4) JP2010528002A (en)
DK (1) DK3345607T3 (en)
ES (2) ES2666650T3 (en)
FI (1) FI3345607T3 (en)
HU (1) HUE060822T2 (en)
LT (1) LT3345607T (en)
PL (1) PL3345607T3 (en)
PT (1) PT3345607T (en)
SI (1) SI3345607T1 (en)
WO (1) WO2009131553A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE481487T1 (en) 1998-11-27 2010-10-15 Ucb Sa COMPOSITIONS AND METHODS FOR INCREASE BONE MINERALIZATION
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
US7585501B2 (en) * 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
AU2005279772A1 (en) 2004-08-30 2006-03-09 Spineovations, Inc. Method of treating spinal internal disk derangement
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP3345607B1 (en) 2006-12-29 2022-10-26 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
CL2008002775A1 (en) 2007-09-17 2008-11-07 Amgen Inc Use of a sclerostin binding agent to inhibit bone resorption.
TWI489993B (en) 2007-10-12 2015-07-01 Novartis Ag Compositions and methods of use for antibodies against sclerostin
AU2008330125B2 (en) * 2007-11-21 2012-11-22 Amgen Inc. Wise binding antibodies and epitopes
US8469961B2 (en) * 2008-03-05 2013-06-25 Neville Alleyne Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints
WO2010115932A1 (en) * 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
EP2558106A1 (en) * 2010-04-16 2013-02-20 Novartis AG Methods and compositions for improving implant osseointegration
SMT202000095T1 (en) 2010-05-14 2020-03-13 Amgen Inc High concentration anti-sclerostin antibody formulations
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
EA201391248A1 (en) 2011-03-01 2014-05-30 Эмджен Инк. BISPECIFIC BINDING AGENTS
AP3981A (en) 2011-03-25 2017-01-05 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
SI2739311T1 (en) 2011-08-04 2018-07-31 Amgen Inc. Method for treating bone gap defects
EP3712168A3 (en) 2011-12-28 2020-10-14 Amgen Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
AU2013285488B2 (en) 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
US9770415B2 (en) * 2012-11-27 2017-09-26 Southwest Research Institute Delivery substrates from aligned polymer biomaterials for tissue repair
AU2014212081A1 (en) * 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
MA41142A (en) 2014-12-12 2017-10-17 Amgen Inc ANTI-SCLEROSTINE ANTIBODIES AND THE USE OF THEM TO TREAT BONE CONDITIONS AS PART OF THE TREATMENT PROTOCOL
WO2016115532A1 (en) 2015-01-16 2016-07-21 Spineovations, Inc. Method of treating spinal disk
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CN106202901A (en) * 2016-07-04 2016-12-07 奥美之路(北京)健康科技股份有限公司 Stone age remote online interpreting system
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
EP3754021A4 (en) 2018-02-12 2021-11-10 Aptacure Therapeutics Limited APTAMER FOR SCLEROSTIN AND USE OF IT
EP3774879B1 (en) 2018-03-30 2026-01-28 Amgen Inc. C-terminal antibody variants
US20220133957A1 (en) * 2019-02-04 2022-05-05 Emory University Sclerostin Inhibitors That Promote Bone Morphogenetic Protein Expression
CN114364694B (en) * 2019-07-12 2024-05-10 国立大学法人京都大学 Neutralizing antibodies for tooth regeneration therapy targeting USAG-1 molecules
CN111658821A (en) * 2020-06-03 2020-09-15 深圳市百吉因生物科技有限公司 Small-interference RNA-loaded collagen-based bone repair material, preparation method and application in preparation of material for treating osteoporosis and fracture
US12611313B2 (en) 2023-04-06 2026-04-28 33 Medical, Inc. Minimally invasive compliant devices for total lumbar disc replacement
KR20260021016A (en) 2023-06-02 2026-02-12 33 메디칼, 인크. Composition for the treatment of intervertebral disc pain, and method for its preparation and use

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039534A1 (en) * 2001-11-08 2003-05-15 Merck & Co., Inc. Compositions and methods for treating osteoporosis
WO2003073991A2 (en) * 2002-03-01 2003-09-12 Celltech R & D, Inc. Methods to increase or decrease bone density
WO2003106657A2 (en) * 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
WO2005003158A2 (en) * 2003-06-16 2005-01-13 Celltech R & D, Inc. Compositions and methods for increasing bone mineralization
WO2006102070A2 (en) * 2005-03-18 2006-09-28 Enzo Biochem, Inc. Sclerostin and the inhibition of wnt signaling and bone formation
WO2006119107A2 (en) * 2005-05-03 2006-11-09 Ucb Pharma S.A. Sclerostin binding agents
US20070292444A1 (en) * 2003-06-16 2007-12-20 Stowers Institute For Medical Research Peptides for treatment and diagnosis of bone diseases
WO2008133722A2 (en) * 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0054540A1 (en) 1980-04-07 1982-06-30 BERMAN Joel d/b/a JOEL BERMAN ASSOCIATES Window shade roller assembly
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0381296B1 (en) 1984-04-30 1994-11-30 THE PROCTER & GAMBLE COMPANY Kit for use in the treatment of osteoporosis
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5324819A (en) 1988-04-08 1994-06-28 Stryker Corporation Osteogenic proteins
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5344654A (en) * 1988-04-08 1994-09-06 Stryker Corporation Prosthetic devices having enhanced osteogenic properties
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5298852A (en) 1988-12-22 1994-03-29 Robert Bosch Gmbh Arrangement for and method of controlling a three-phase-generator in a vehicle
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5561173A (en) * 1990-06-19 1996-10-01 Carolyn M. Dry Self-repairing, reinforced matrix materials
CA2082160C (en) * 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
US5656593A (en) 1991-03-11 1997-08-12 Creative Biomolecules, Inc. Morphogen induced periodontal tissue regeneration
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993009229A1 (en) * 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
CA2130436C (en) 1992-02-19 2001-04-10 John S. Abrams Cloning and expression of humanized monoclonal antibodies against human interleukin-4
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
IT1255522B (en) 1992-09-24 1995-11-09 Ubaldo Conte COMPRESSED FOR THERAPEUTIC USE SUITABLE FOR SELLING ONE OR MORE ACTIVE SUBSTANCES WITH DIFFERENT SPEEDS
AU671721B2 (en) * 1993-01-12 1996-09-05 Genentech Inc. Tgf-beta formulation for inducing bone growth
TW303299B (en) * 1993-07-22 1997-04-21 Lilly Co Eli
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5550134A (en) * 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss
DE19647853A1 (en) * 1996-11-19 1998-05-20 Bioph Biotech Entw Pharm Gmbh Compounds with improved cartilage and / or bone inducing activity
US5939039A (en) 1997-01-16 1999-08-17 Orthovita, Inc. Methods for production of calcium phosphate
JP4388602B2 (en) * 1997-02-07 2009-12-24 ストライカー コーポレイション Bone-forming device not containing matrix, graft, and method of use thereof
US20020098222A1 (en) * 1997-03-13 2002-07-25 John F. Wironen Bone paste
US7041641B2 (en) * 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
ATE250434T1 (en) * 1997-04-22 2003-10-15 Washington Res Found BONE TRANSPLANTS AND PROSTHESES COATED WITH TARTRATE-RESISTANT ACID PHOSPHATASE
US6025538A (en) * 1998-11-20 2000-02-15 Musculoskeletal Transplant Foundation Compound bone structure fabricated from allograft tissue
ATE481487T1 (en) 1998-11-27 2010-10-15 Ucb Sa COMPOSITIONS AND METHODS FOR INCREASE BONE MINERALIZATION
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20030082233A1 (en) * 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
US20020169122A1 (en) 2001-02-23 2002-11-14 Wyeth Chondrogenic potential of human bone marrow-derived CD105+ cells by BMP
US6949251B2 (en) 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
WO2002092000A2 (en) 2001-05-11 2002-11-21 Genome Therapeutics Corporation Hbm variants that modulate bone mass and lipid levels
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
EP2295081B1 (en) * 2001-06-26 2018-10-31 Amgen Inc. Antibodies to OPGL
WO2003070288A2 (en) * 2001-10-12 2003-08-28 Inframat Corporation Coated implants and methods of coating implants
EP1531855A4 (en) * 2002-01-10 2009-07-22 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
JP2005519067A (en) * 2002-01-17 2005-06-30 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Stimulation of bone growth and cartilage formation using thrombin peptide derivatives
JP3646167B2 (en) * 2002-02-19 2005-05-11 独立行政法人産業技術総合研究所 Composite biomaterials containing phosphophorin
US7166133B2 (en) * 2002-06-13 2007-01-23 Kensey Nash Corporation Devices and methods for treating defects in the tissue of a living being
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
US20040002770A1 (en) 2002-06-28 2004-01-01 King Richard S. Polymer-bioceramic composite for orthopaedic applications and method of manufacture thereof
JP2005532395A (en) * 2002-07-02 2005-10-27 スミスクライン・ビーチャム・コーポレイション New stable formulation
US20040023322A1 (en) * 2002-08-01 2004-02-05 Goodheart Clyde R. Method of producing non-recombinant BMP-2 and use thereof
KR20040023356A (en) 2002-09-11 2004-03-18 현대모비스 주식회사 a gear-lever locking system and a method thereof in a locking parking-brake
JP2006503615A (en) 2002-09-30 2006-02-02 リージェン バイオテック インコーポレーテッド Bone filling composition for promoting bone formation and osteosclerosis comprising calcium sulfate and a viscous polymer
JP3851602B2 (en) * 2002-10-02 2006-11-29 ペンタックス株式会社 Osteogenic treatment device
JP2007525953A (en) 2003-06-06 2007-09-13 ワイス Methods and materials for identifying substances that modulate bone remodeling, and substances identified thereby
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US7943393B2 (en) 2003-07-14 2011-05-17 Phynexus, Inc. Method and device for extracting an analyte
US6976816B2 (en) 2003-08-01 2005-12-20 Dana Corporation Combination lock washer and spindle bearing assembly
MY141763A (en) * 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
WO2005070439A1 (en) * 2004-01-09 2005-08-04 Regeneration Technologies Inc. Implant comprising a human muscle tissue matrix
US7189263B2 (en) 2004-02-03 2007-03-13 Vita Special Purpose Corporation Biocompatible bone graft material
US7531518B2 (en) * 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7648965B2 (en) * 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
AU2005250441A1 (en) * 2004-05-27 2005-12-15 Acceleron Pharma Inc. TGF derepressors and uses related thereto
WO2006015373A2 (en) 2004-08-04 2006-02-09 Amgen Inc Antibodies to dkk-1
JP2008517660A (en) * 2004-10-22 2008-05-29 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ Hollow and porous orthopedic or dental implants for delivering biological agents
MX2007008319A (en) * 2005-01-06 2007-10-04 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures.
US7531533B2 (en) * 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
US8071574B2 (en) 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US20060198863A1 (en) 2005-03-03 2006-09-07 Musculoskeletal Transplant Foundation Ceramic composition for filling bone defects
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
JP2006320442A (en) 2005-05-18 2006-11-30 Toshiba Ceramics Co Ltd Calcium phosphate bone filling material
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
WO2006135734A2 (en) 2005-06-10 2006-12-21 The Regents Of The University Of California Compositions and methods for altering bone density and bone patterning
NZ564098A (en) * 2005-06-15 2010-04-30 Schering Corp Anti-IGF1R antibody formulations
CN103349793B (en) 2005-09-09 2016-02-10 阿格诺沃斯健康关爱公司 Composite bone graft substitute cement and the goods obtained by it
KR20080084808A (en) 2005-11-17 2008-09-19 바이오미메틱 세라퓨틱스, 인크. Maxillary facial bone reinforcement using ｒｈＰＤＧＦ-ＢＢ and biocompatible matrix
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
BRPI0620316A2 (en) 2005-12-21 2011-11-08 Wyeth Corp Low viscosity protein formulations and their uses
EP3345607B1 (en) * 2006-12-29 2022-10-26 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
MY149129A (en) 2007-03-20 2013-07-15 Lilly Co Eli Anti-sclerostin antibodies
WO2008133618A1 (en) 2007-04-27 2008-11-06 Unigene Laboratories, Inc. Methods and compositions for fostering and preserving bone growth
CL2008002775A1 (en) 2007-09-17 2008-11-07 Amgen Inc Use of a sclerostin binding agent to inhibit bone resorption.
TWI489993B (en) * 2007-10-12 2015-07-01 Novartis Ag Compositions and methods of use for antibodies against sclerostin
TWI452136B (en) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JP6511233B2 (en) 2014-08-28 2019-05-15 株式会社竹中工務店 Joint structure of column base and steel beam

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039534A1 (en) * 2001-11-08 2003-05-15 Merck & Co., Inc. Compositions and methods for treating osteoporosis
WO2003073991A2 (en) * 2002-03-01 2003-09-12 Celltech R & D, Inc. Methods to increase or decrease bone density
WO2003106657A2 (en) * 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
WO2005003158A2 (en) * 2003-06-16 2005-01-13 Celltech R & D, Inc. Compositions and methods for increasing bone mineralization
US20070292444A1 (en) * 2003-06-16 2007-12-20 Stowers Institute For Medical Research Peptides for treatment and diagnosis of bone diseases
WO2006102070A2 (en) * 2005-03-18 2006-09-28 Enzo Biochem, Inc. Sclerostin and the inhibition of wnt signaling and bone formation
WO2006119107A2 (en) * 2005-05-03 2006-11-09 Ucb Pharma S.A. Sclerostin binding agents
WO2008133722A2 (en) * 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BALEMANS W ET AL: "INCREASED BONE DENSITY IN SCLEROSTEOSIS IS DUE TO THE DEFICIENCY OFA NOVEL SECRETED PROTEIN (SOST)", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, vol. 10, no. 5, 1 January 2001 (2001-01-01), pages 537 - 543, XP001058218, ISSN: 0964-6906 *
BEZOOIJEN R L V ET AL: "SOST/sclerostin, an osteocyte-derived negative regulator of bone formation", CYTOKINE AND GROWTH FACTOR REVIEWS, OXFORD, GB, vol. 16, no. 3, 1 June 2005 (2005-06-01), pages 319 - 327, XP004964512, ISSN: 1359-6101 *
DÍEZ J L: "Skeletal effects of selective oestrogen receptor modulators (SERMs).", HUMAN REPRODUCTION UPDATE 2000 MAY-JUN, vol. 6, no. 3, May 2000 (2000-05-01), pages 255 - 258, XP002570654, ISSN: 1355-4786 *
ELLIES DEBRA L ET AL: "Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.", JOURNAL OF BONE AND MINERAL RESEARCH : THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH NOV 2006, vol. 21, no. 11, November 2006 (2006-11-01), pages 1738 - 1749, XP002554008, ISSN: 0884-0431 *
HEANEY ROBERT P: "Advances in therapy for osteoporosis.", CLINICAL MEDICINE & RESEARCH APR 2003, vol. 1, no. 2, April 2003 (2003-04-01), pages 93 - 99, XP002570652, ISSN: 1539-4182 *
HOSKING D J ET AL: "Osteoporosis therapy: an example of putting evidence-based medicine into clinical practice.", QJM : MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS JUN 2005, vol. 98, no. 6, June 2005 (2005-06-01), pages 403 - 413, XP002570651, ISSN: 1460-2725 *
KHOSLA S ET AL: "TREATMENT OPTIONS FOR OSTEOPOROSIS", MAYO CLINIC PROCEEDINGS, MAYO MEDICAL VENTURES, ROCHESTER, MN, vol. 70, no. 10, 1 January 1995 (1995-01-01), pages 978 - 982, XP009009909, ISSN: 0025-6196 *
MACDONALD B R ET AL: "Emerging therapies in osteoporosis.", BEST PRACTICE & RESEARCH. CLINICAL RHEUMATOLOGY JUL 2001, vol. 15, no. 3, July 2001 (2001-07-01), pages 483 - 496, XP002570653, ISSN: 1521-6942 *
POOLE KENNETH E S ET AL: "Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 19, no. 13, 1 November 2005 (2005-11-01), pages 1(1842 - 1844), XP002501738, ISSN: 0892-6638, [retrieved on 20080825] *
VAN BEZOOIJEN RUTGER L ET AL: "WNT BUT NOT BMP SIGNALING IS INVOLVED IN THE INHIBITORY ACTION OF SCLEROSTIN ON BMP-STIMULATED BONE FORMATION", JOURNAL OF BONE AND MINERAL RESEARCH, AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH, NEW YORK, NY, US, vol. 22, no. 1, January 2007 (2007-01-01), pages 19 - 28, XP008078168, ISSN: 0884-0431 *

Also Published As

Publication number Publication date
US20170044248A1 (en) 2017-02-16
FI3345607T3 (en) 2022-11-30
EP2144613A2 (en) 2010-01-20
JP2014074046A (en) 2014-04-24
WO2009131553A2 (en) 2009-10-29
US8178099B2 (en) 2012-05-15
US20260062470A1 (en) 2026-03-05
JP2010528002A (en) 2010-08-19
PT3345607T (en) 2022-11-21
US20240360207A1 (en) 2024-10-31
JP2018199725A (en) 2018-12-20
EP3345607A1 (en) 2018-07-11
EP4176884A1 (en) 2023-05-10
US11608373B2 (en) 2023-03-21
PL3345607T3 (en) 2023-01-09
US20230357377A1 (en) 2023-11-09
DK3345607T3 (en) 2022-11-21
US20150086571A1 (en) 2015-03-26
ES2930183T3 (en) 2022-12-07
EP3345607B1 (en) 2022-10-26
HUE060822T2 (en) 2023-04-28
JP2017014263A (en) 2017-01-19
SI3345607T1 (en) 2023-03-31
US11891438B2 (en) 2024-02-06
US20080160060A1 (en) 2008-07-03
US20130195856A1 (en) 2013-08-01
US20230226086A1 (en) 2023-07-20
US8877196B2 (en) 2014-11-04
EP2144613B1 (en) 2018-03-21
US20120201815A1 (en) 2012-08-09
US11807681B2 (en) 2023-11-07
ES2666650T3 (en) 2018-05-07
LT3345607T (en) 2023-01-10

Similar Documents

Publication Publication Date Title
WO2009131553A3 (en) Methods of altering bone growth by administration of sost or wise antagonist or agonist
NZ592475A (en) An implant for treating obstructive sleep apnea with arms extending through the tongue and being anchored to inframandibular musculature
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
EP2371853A3 (en) Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
NZ707292A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
MX2010005271A (en) Adjustable tissue support member.
WO2006023803A3 (en) Methods of administering microparticles combined with autologous body components
WO2007133520A3 (en) Stent coating comprising titanium oxide or iridium oxide and a therapeutic agent
WO2010107794A3 (en) Compositions and methods for delivering an agent to a wound
WO2007143231A3 (en) Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2004084709A3 (en) Devices, systems, and methods to fixate tissue within the regions of body, such as the pharyngeal conduit
WO2012142517A3 (en) Polyaxial dental implant system
EP2420568A3 (en) Methods and compositions for treatment of bone defects with placental cell populations
DE602007010340D1 (en) IMPLANT MEDICAL LONG TERM ELEMENT WITH EXPANDABLE FASTENERS
NZ606825A (en) Methods and compositions for treating complement-associated disorders
WO2011146926A3 (en) Systems and methods for treatment of sleep apnea
ATE539676T1 (en) DEVICE FOR ADMINISTRATION OF AN IMPLANTABLE MONITOR
BR112014015268A8 (en) implantable dental device and method to implant in a patient's mouth
UA105502C2 (en) Implantable device for the delivery of octreotide and methods of use thereof
WO2012020412A3 (en) Fibrin based scaffold, preparation and use thereof
WO2011116384A3 (en) Systems and methods for treatment of sleep apnea
WO2014018441A3 (en) Porous metal dental implant
NZ583803A (en) Agents with angiogenic and wound healing activity
MX2010010799A (en) Methods of diagnosing, preventing and treating bone mass diseases.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2010509325

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007875255

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07875255

Country of ref document: EP

Kind code of ref document: A2